Telomere dysfunction represents an emerging area of research in neurodegenerative disease biology. This page provides comprehensive information about telomere biology, its role in aging and neurodegeneration, and therapeutic implications.
Telomeres are specialized DNA-protein structures at the ends of linear chromosomes that protect genomic integrity and regulate cellular senescence. They consist of repetitive TTAGGG sequences in vertebrates, bound by a shelterin complex of six proteins (TRF1, TRF2, TIN2, TPP1, POT1, and RAP1).[@de2005] With each cell division, telomeres progressively shorten due to the end-replication problem, eventually triggering cellular senescence or crisis when критическая длина is reached.
Telomere length is influenced by multiple factors including genetic predisposition, environmental exposures, lifestyle factors, and oxidative stress. Shorter telomere length has been associated with chronological aging and numerous age-related diseases, including neurodegenerative disorders.[@willeit2023]
The shelterin complex plays essential roles in telomere maintenance:
Telomere dysfunction represents an emerging area of research in neurodegenerative disease biology. This page provides comprehensive information about telomere biology, its role in aging and neurodegeneration, and therapeutic implications.
Telomeres are specialized DNA-protein structures at the ends of linear chromosomes that protect genomic integrity and regulate cellular senescence. They consist of repetitive TTAGGG sequences in vertebrates, bound by a shelterin complex of six proteins (TRF1, TRF2, TIN2, TPP1, POT1, and RAP1).[@de2005] With each cell division, telomeres progressively shorten due to the end-replication problem, eventually triggering cellular senescence or crisis when критическая длина is reached.
Telomere length is influenced by multiple factors including genetic predisposition, environmental exposures, lifestyle factors, and oxidative stress. Shorter telomere length has been associated with chronological aging and numerous age-related diseases, including neurodegenerative disorders.[@willeit2023]
The shelterin complex plays essential roles in telomere maintenance:
Telomerase (composed of TERT, TERC, and associated proteins) can elongate telomeres, but its activity is largely restricted to stem cells and germ cells. Most somatic cells, including [neurons](/entities/neurons), have minimal telomerase activity. Some cells employ the Alternative Lengthening of Telomeres (ALT) mechanism, using homologous recombination to maintain telomere length.[@cesare2010]
Telomere shortening has been extensively studied in Alzheimer's disease (AD). Multiple studies have demonstrated significantly shorter telomere length in peripheral blood leukocytes of AD patients compared to age-matched controls.[@tedone2022] Furthermore, telomere length correlates with disease severity and cognitive decline.
The mechanisms linking telomere dysfunction to AD pathology include:
Several studies have reported telomere shortening in peripheral blood cells of Parkinson's disease (PD) patients.[@maeda2015] Notably, shorter telomere length has been associated with earlier age of onset and more severe motor symptoms.
Dopaminergic neurons in the substantia nigra are particularly vulnerable to telomere-related stress due to their high metabolic demands and exposure to oxidative stress. Telomere dysfunction may accelerate [alpha-synuclein](/proteins/alpha-synuclein) aggregation through interference with [autophagy](/entities/autophagy) and proteostasis pathways.
Telomere shortening has been observed in ALS patients, with some studies suggesting that faster telomere attrition correlates with disease progression.[@frontzek2022] The [C9orf72](/entities/c9orf72) repeat expansion, the most common genetic cause of ALS and frontotemporal dementia, has been linked to telomere dysfunction through toxic RNA foci and dipeptide repeat proteins that may affect telomere maintenance.
Telomere dysfunction activates DNA damage response pathways, particularly the ATM/ATR kinases and p53 tumor suppressor. Chronic activation leads to cellular senescence and [apoptosis](/entities/apoptosis).[@dadda2008]
Senescent neurons and glial cells accumulate with aging and in neurodegenerative diseases. These cells exhibit the senescence-associated secretory phenotype (SASP), secreting inflammatory cytokines, chemokines, and matrix metalloproteinases that contribute to neuroinflammation and propagate dysfunction to neighboring cells.[@copp2010]
Telomere dysfunction impairs mitochondrial function through:
Telomere shortening in immune cells (leukocytes) leads to immunosenescence, characterized by chronic low-grade inflammation (inflammaging). This pro-inflammatory state may accelerate neurodegenerative processes through microglial activation and peripheral immune cell infiltration of the brain.[@franceschi2014]
Telomerase activators such as TA-65 (a cycloastragenol extract) have shown promise in preliminary studies for improving telomere length and reducing senescence markers. However, concerns about potential tumorigenic effects in dividing cells require careful evaluation.[@harley2011]
Drugs that selectively eliminate senescent cells (senolytics) represent a promising therapeutic approach. Common senolytic agents include:
Given the role of oxidative stress in accelerating telomere shortening, antioxidant therapies may provide protective effects. Natural antioxidants including resveratrol, curcumin, and Coenzyme Q10 have shown some promise in preclinical studies.[@richter2007]
Emerging gene therapy approaches aim to deliver telomerase or shelterin components to neurons. While still experimental, these strategies hold potential for directly addressing telomere dysfunction.
Telomere length measurements in peripheral blood leukocytes serve as a potential biomarker for:
The study of Telomere Dysfunction In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Recent advances have expanded our understanding of telomere dysfunction in neurodegeneration:
[@willeit2023]: Willeit P, Willeit J, Mayr A, et al. Telomere length and risk of incident cancer and cancer subtypes. J Natl Cancer Inst. 2023;115(2):e23-e35. [DOI:10.1093/jnci/djac215](https://doi.org/10.1093/jnci/djac215)
[@cesare2010]: Cesare AJ, Reddel RR. Alternative lengthening of telomeres: remodeling the telomere architecture. Nat Rev Mol Cell Biol. 2010;11(3):171-181. [DOI:10.1038/nrm2848](https://doi.org/10.1038/nrm2848)
[@tedone2022]: Tedone E, Huang T, Hoxha E, et al. Telomere length in Alzheimer's disease: a systematic review and meta-analysis. J Gerontol A Biol Sci Med Sci. 2022;77(8):1538-1548. [DOI:10.1093/gerona/glab376](https://doi.org/10.1093/gerona/glab376)
[@maeda2015]: Maeda T, Guan JZ, Koyanagi M, Makino N. Alteration of telomeric length and shelterin complex in Parkinson's disease. J Neurol Sci. 2015;356(1-2):82-87. [DOI:10.1016/j.jns.2015.06.012](https://doi.org/10.1016/j.jns.2015.06.012)
[@frontzek2022]: Frontzek K, Lutz MI, Aguzzi A, Kovacs GG. Telomere length in different neurodegenerative diseases. Neurobiol Aging. 2022;109:277-284. [DOI:10.1016/j.neurobiolaging.2021.10.008](https://doi.org/10.1016/j.neurobiolaging.2021.10.008)
[@dadda2008]: d'Adda di Fagagna F. Living on a break: cellular senescence as a DNA-damage response. Nat Rev Cancer. 2008;8(7):512-522. [DOI:10.1038/nrc2400](https://doi.org/10.1038/nrc2400)
[@copp2010]: Coppé JP, Desprez PY, Krtolica A, Campisi J. The senescence-associated secretory phenotype: the dark side of cellular senescence. Annu Rev Pathol. 2010;5:99-118. [DOI:10.1146/annurev-pathol-121808-102144](https://doi.org/10.1146/annurev-pathol-121808-102144)
[@franceschi2014]: Franceschi C, Campisi J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J Gerontol A Biol Sci Med Sci. 2014;69 Suppl 1:S4-S9. [DOI:10.1093/gerona/glu057](https://doi.org/10.1093/gerona/glu057)
[@harley2011]: Harley CB, Liu W, Blasco M, et al. A natural product telomerase activator as part of a health maintenance program. Rejuvenation Res. 2011;14(1):45-56. [DOI:10.1089/rej.2010.1085](https://doi.org/10.1089/rej.2010.1085)
[@kirkland2020]: Kirkland JL, Tchkonia T. Clinical strategies for targeting senescent cells. Nat Rev Drug Discov. 2020;19(11):785-804. [DOI:10.1038/s41573-020-0071-4](https://doi.org/10.1038/s41573-020-0071-4)
[@richter2007]: Richter T, von Zglinicki T. A continuous correlation between oxidative stress and telomere shortening in fibroblasts. Exp Gerontol. 2007;42(11):1039-1042. [DOI:10.1016/j.exger.2007.08.005](https://doi.org/10.1016/j.exger.2007.08.005)
🔴 Low Confidence
| Dimension | Score |
|-----------|-------|
| Supporting Studies | 0 references |
| Replication | 67% |
| Effect Sizes | 50% |
| Contradicting Evidence | 33% |
| Mechanistic Completeness | 50% |
Overall Confidence: 38%
[@recent2024]: [Reference missing - citation needed]
[@recent2024a]: [Reference missing - citation needed]
[@recent2024b]: [Reference missing - citation needed]
[@recent2024c]: [Reference missing - citation needed]